Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$1.19M$1.19M+11.6% vs Q2 2015 Net Income-$1.31M-$1.31MN/M vs Q2 2015 EPS Diluted-$0.02-$0.02N/M vs Q2 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$811,000N/M Free Cash Flowderived-$842,000N/M Margins · derivedGross margin2.5%+6.1 pt vs Q2 2015
Operating margin-118.6%−22.8 pt vs Q2 2015
Net margin-110.3%−25.2 pt vs Q2 2015
ended Dec 31, 2015 · filed Feb 9, 2016 · 40 d after period end